AU2006278759B2 - Pyrimidine compounds as serotonin receptor modulators - Google Patents

Pyrimidine compounds as serotonin receptor modulators Download PDF

Info

Publication number
AU2006278759B2
AU2006278759B2 AU2006278759A AU2006278759A AU2006278759B2 AU 2006278759 B2 AU2006278759 B2 AU 2006278759B2 AU 2006278759 A AU2006278759 A AU 2006278759A AU 2006278759 A AU2006278759 A AU 2006278759A AU 2006278759 B2 AU2006278759 B2 AU 2006278759B2
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
substituted
pyrido
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006278759A
Other languages
English (en)
Other versions
AU2006278759A1 (en
Inventor
Curt A. Dvorak
Dale A. Rudolph
Brock T. Shireman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2006278759A1 publication Critical patent/AU2006278759A1/en
Application granted granted Critical
Publication of AU2006278759B2 publication Critical patent/AU2006278759B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
AU2006278759A 2005-08-04 2006-07-27 Pyrimidine compounds as serotonin receptor modulators Ceased AU2006278759B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70571905P 2005-08-04 2005-08-04
US60/705,719 2005-08-04
PCT/US2006/029437 WO2007019083A1 (en) 2005-08-04 2006-07-27 Pyrimidine compounds as serotonin receptor modulators

Publications (2)

Publication Number Publication Date
AU2006278759A1 AU2006278759A1 (en) 2007-02-15
AU2006278759B2 true AU2006278759B2 (en) 2012-08-16

Family

ID=37400981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006278759A Ceased AU2006278759B2 (en) 2005-08-04 2006-07-27 Pyrimidine compounds as serotonin receptor modulators

Country Status (16)

Country Link
EP (1) EP1928461B1 (enExample)
JP (1) JP5066088B2 (enExample)
KR (1) KR101353268B1 (enExample)
CN (1) CN101277700B (enExample)
AT (1) ATE539753T1 (enExample)
AU (1) AU2006278759B2 (enExample)
BR (1) BRPI0614397A2 (enExample)
CA (1) CA2617760C (enExample)
CR (1) CR9791A (enExample)
EA (1) EA014495B1 (enExample)
IL (2) IL189164A (enExample)
NO (1) NO340744B1 (enExample)
NZ (1) NZ565334A (enExample)
UA (1) UA95247C2 (enExample)
WO (1) WO2007019083A1 (enExample)
ZA (1) ZA200802010B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004019118D1 (de) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7928099B2 (en) 2007-03-23 2011-04-19 Pfizer Inc Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
RU2015140748A (ru) * 2010-05-21 2018-12-26 Эббви Инк. Модуляторы 5-нт рецепторов и способы их применения
JP5851663B1 (ja) 2014-05-29 2016-02-03 大鵬薬品工業株式会社 新規テトラヒドロピリドピリミジン化合物又はその塩
CN107365314B (zh) * 2016-05-11 2024-09-27 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
EP3541790B1 (en) * 2016-11-15 2025-09-03 Temple University - Of The Commonwealth System of Higher Education 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression
NZ759297A (en) 2017-05-31 2026-03-27 Chemocentryx Inc 6-5 fused rings as c5a inhibitors
WO2019126424A1 (en) * 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
KR102282569B1 (ko) * 2019-02-08 2021-07-29 (주)퓨쳐켐 새로운 18F-표지된 친디엔체와 테트라진 화합물과의 IeDDA 반응을 이용한 18F-표지 방법
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
KR102483492B1 (ko) * 2019-09-02 2023-01-02 한양대학교 에리카산학협력단 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물
MX2022005819A (es) * 2019-11-13 2022-08-16 Univ Temple Nuevas lactonas funcionalizadas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso.
EP4313967B1 (en) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Khk inhibitors
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
WO2002072558A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Antithrombotische carbonsäureamide, deren herstellung und deren verwendung als arzneimittel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148265A (ja) * 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
MX9605218A (es) * 1994-04-29 1997-10-31 Pfizer Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores.
AU2980797A (en) * 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US6806230B1 (en) * 1999-09-09 2004-10-19 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives and herbicides containing them
AU2001241128A1 (en) * 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
DE602004019118D1 (de) * 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
WO2002072558A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Antithrombotische carbonsäureamide, deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
CN101277700A (zh) 2008-10-01
HK1118469A1 (en) 2009-02-13
JP2009503076A (ja) 2009-01-29
CN101277700B (zh) 2013-02-20
UA95247C2 (ru) 2011-07-25
EP1928461B1 (en) 2012-01-04
EP1928461A1 (en) 2008-06-11
CR9791A (es) 2010-05-27
BRPI0614397A2 (pt) 2011-03-29
NZ565334A (en) 2010-12-24
NO340744B1 (no) 2017-06-12
AU2006278759A1 (en) 2007-02-15
WO2007019083A1 (en) 2007-02-15
ATE539753T1 (de) 2012-01-15
CA2617760C (en) 2015-02-17
CA2617760A1 (en) 2007-02-15
KR101353268B1 (ko) 2014-02-06
NO20081034L (no) 2008-02-28
JP5066088B2 (ja) 2012-11-07
KR20080033502A (ko) 2008-04-16
ZA200802010B (en) 2009-09-30
EA200800525A1 (ru) 2008-06-30
IL189164A0 (en) 2008-08-07
EA014495B1 (ru) 2010-12-30
IL213679A0 (en) 2011-07-31
IL189164A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
US7598255B2 (en) Pyrimidine compounds as serotonin receptor modulators
US8618288B2 (en) Pyrimidine compounds as serotonin receptor modulators
IL189164A (en) 4–4– (Fluoro-phenyl) –2 – Isopropyl – 5,6,7,8 – Tetrahydro-Pyrido [4,3– d] –Pyrimidine and Pharmaceutical Preparation Containing It
DK2421533T3 (en) Hitherto unknown anti-inflammatory agents
KR20150027267A (ko) LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
JP2010526138A (ja) ピロロピリミジン−７−オン誘導体とその薬剤としての使用
WO2015015318A2 (en) Novel quinazolinones as bromodomain inhibitors
CN101652367A (zh) 作为5-ht2c激动剂的嘧啶并[4,5-d]氮杂卓衍生物
AU2006259257A1 (en) Hexahydro-pyrrolo-isoquinoline compounds for the treatment of CNS disorders
CN1882590B (zh) 作为血清素受体调节剂的稠合杂环化合物
HK1118469B (en) Pyrimidine compounds as serotonin receptor modulators
HK1141024A (en) Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists
HK40003375A (en) Novel anti-inflammatory agents
HK40003375B (en) Novel anti-inflammatory agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired